Non-small Cell Lung Cancer Therapeutics Market Size, Share, Growth, Trends and Forecast Report

The
global non-small cell lung cancer therapeutics market is
expected to reach a value of USD 12.2 billion by 2025, based on a new report by
Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market
is anticipated to witness significant growth during the forecast period. This
can be attributed to the high investment by market players in the research and
development of lung cancer therapy, presence of a rich pipeline, and increasing
penetration of drugs during the forecast period.
Introduction
of several drugs in various geographical regions is likely to drive the market
during the forecast period. For instance, in October 2016, the FDA granted
Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by
Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has
been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and
Israel.
Presence of
a strong pipeline of drugs for non-small cell lung cancer helps propel the
market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation,
Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major
molecules in the pipeline.
Further key
findings from the study suggest:
- By drug, Alimta
accounted for the highest share in 2015. However, it is expected to
witness decline in its share during the forecast period.
- Alecensa
(alectinib) is expected to grow at the highest rate during the forecast
period. This is majorly attributed to the clinical benefit of the drug to
treat ALK-positive NSCLC.
- Alecensa is
expected to be a competitor to Pfizer’s Xalkori and Merck’s Keytruda during
the forecast period. A superior progression-free survival rate of Alecensa
was observed in the clinical
trials as compared to Crizotinib.
- Geographically,
North America dominated the overall industry in 2015. This is due to the
early entry of drugs in the market, increased adoption of new treatment,
and high cost of the drug.
- It is expected
that North America would maintain its dominance during the forecast period
and grow with the highest rate over the coming years due to expected entry
of new drugs.
- Several players
are operating in the industry. Geographical penetration and development of
innovative & effective drugs are the key strategies of the players to
increase their share.
- Some of the key
players are GlaxoSmithKline (GSK) Plc., Novartis AG, AstraZeneca, F.
Hoffmann-La Roche AG, Bristol-Myers Squibb, Pfizer Inc., Eli Lilly &
Company, and Sanofi.
Access full
research report on global non-small cell lung cancer therapeutics market:
www.grandviewresearch.com/industry-analysis/non-small-cell-lung-cancer-nsclc-therapeutics-market
Comments